EGFR and non-small cell lung carcinoma: The efficacy of ICI as second‐line treatment after EGFR‐TKI for EGFR mutation‐positive NSCLC has not been fully validated, and EGFR‐positive NSCLC has been ruled out in many clinical studies of ICI.